| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 74 | 2024 | 519 | 13.270 |
Why?
|
| Antitubercular Agents | 59 | 2023 | 247 | 6.930 |
Why?
|
| Tuberculin Test | 40 | 2023 | 125 | 5.060 |
Why?
|
| Latent Tuberculosis | 14 | 2023 | 74 | 4.990 |
Why?
|
| Mycobacterium tuberculosis | 36 | 2022 | 378 | 4.380 |
Why?
|
| Tuberculosis, Pulmonary | 38 | 2021 | 216 | 4.330 |
Why?
|
| Interferon-gamma Release Tests | 13 | 2023 | 82 | 3.490 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 8 | 2021 | 46 | 2.310 |
Why?
|
| Isoniazid | 9 | 2021 | 62 | 2.060 |
Why?
|
| Rifampin | 7 | 2021 | 129 | 2.000 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 12 | 2023 | 68 | 1.870 |
Why?
|
| Child | 125 | 2025 | 24453 | 1.670 |
Why?
|
| Directly Observed Therapy | 10 | 2018 | 24 | 1.480 |
Why?
|
| Child, Preschool | 77 | 2025 | 14050 | 1.460 |
Why?
|
| Mycobacterium Infections | 7 | 2010 | 31 | 1.300 |
Why?
|
| Antibiotics, Antitubercular | 3 | 2016 | 33 | 1.170 |
Why?
|
| Mass Screening | 11 | 2021 | 785 | 1.160 |
Why?
|
| Tuberculosis, Pleural | 2 | 2022 | 8 | 1.160 |
Why?
|
| Adolescent | 72 | 2025 | 19329 | 1.120 |
Why?
|
| Humans | 175 | 2025 | 124793 | 1.110 |
Why?
|
| Infant | 58 | 2025 | 12482 | 1.100 |
Why?
|
| Lymphadenitis | 7 | 2014 | 26 | 1.010 |
Why?
|
| Tuberculosis, Meningeal | 7 | 2025 | 29 | 1.010 |
Why?
|
| Mycobacterium | 4 | 2010 | 28 | 1.000 |
Why?
|
| Contact Tracing | 5 | 2021 | 54 | 0.970 |
Why?
|
| BCG Vaccine | 8 | 2021 | 109 | 0.960 |
Why?
|
| Fever | 2 | 2019 | 296 | 0.940 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 4 | 2019 | 23 | 0.860 |
Why?
|
| Texas | 23 | 2020 | 3590 | 0.830 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2022 | 18 | 0.820 |
Why?
|
| Cost of Illness | 2 | 2014 | 248 | 0.810 |
Why?
|
| Drug Administration Schedule | 11 | 2019 | 731 | 0.810 |
Why?
|
| Mycobacterium abscessus | 2 | 2019 | 6 | 0.800 |
Why?
|
| Tuberculosis, Miliary | 2 | 2019 | 10 | 0.790 |
Why?
|
| Tuberculoma | 2 | 2019 | 3 | 0.750 |
Why?
|
| School Health Services | 4 | 2018 | 101 | 0.700 |
Why?
|
| Knee | 1 | 2019 | 17 | 0.660 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2019 | 11 | 0.640 |
Why?
|
| Central Nervous System Infections | 1 | 2019 | 21 | 0.640 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2024 | 240 | 0.620 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2019 | 79 | 0.620 |
Why?
|
| Female | 71 | 2025 | 66553 | 0.610 |
Why?
|
| Drug Monitoring | 3 | 2019 | 170 | 0.610 |
Why?
|
| Edema | 1 | 2019 | 136 | 0.610 |
Why?
|
| Incidence | 17 | 2020 | 3144 | 0.600 |
Why?
|
| Male | 67 | 2025 | 61283 | 0.600 |
Why?
|
| Tuberculin | 1 | 2018 | 8 | 0.590 |
Why?
|
| Interferon-gamma | 5 | 2020 | 503 | 0.590 |
Why?
|
| Medication Adherence | 5 | 2018 | 401 | 0.590 |
Why?
|
| Risk Factors | 28 | 2018 | 10272 | 0.580 |
Why?
|
| Infection Control | 4 | 2013 | 159 | 0.560 |
Why?
|
| Emigrants and Immigrants | 4 | 2014 | 145 | 0.560 |
Why?
|
| Hospitals, Pediatric | 9 | 2018 | 775 | 0.540 |
Why?
|
| Infant, Newborn | 21 | 2025 | 8182 | 0.510 |
Why?
|
| Professional Impairment | 1 | 2015 | 3 | 0.500 |
Why?
|
| Global Health | 7 | 2025 | 558 | 0.500 |
Why?
|
| Illness Behavior | 1 | 2015 | 7 | 0.500 |
Why?
|
| HIV Infections | 12 | 2025 | 1896 | 0.500 |
Why?
|
| Sensitivity and Specificity | 10 | 2021 | 2044 | 0.490 |
Why?
|
| Occupational Health | 1 | 2015 | 44 | 0.490 |
Why?
|
| Rat-Bite Fever | 1 | 2014 | 4 | 0.480 |
Why?
|
| Streptobacillus | 1 | 2014 | 4 | 0.480 |
Why?
|
| Arthralgia | 1 | 2014 | 54 | 0.460 |
Why?
|
| Cross Infection | 6 | 2014 | 329 | 0.460 |
Why?
|
| Age Factors | 13 | 2021 | 2817 | 0.440 |
Why?
|
| Tuberculosis, Central Nervous System | 2 | 2007 | 10 | 0.440 |
Why?
|
| Exanthema | 1 | 2014 | 68 | 0.440 |
Why?
|
| Patient Care | 1 | 2014 | 99 | 0.440 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2022 | 316 | 0.430 |
Why?
|
| Hand Hygiene | 1 | 2013 | 13 | 0.420 |
Why?
|
| Retrospective Studies | 19 | 2021 | 16299 | 0.420 |
Why?
|
| Drug Therapy | 2 | 2012 | 86 | 0.420 |
Why?
|
| Attitude of Health Personnel | 2 | 2015 | 672 | 0.420 |
Why?
|
| Population Surveillance | 2 | 2014 | 389 | 0.400 |
Why?
|
| Anti-Bacterial Agents | 9 | 2022 | 2425 | 0.390 |
Why?
|
| Treatment Outcome | 14 | 2019 | 12342 | 0.390 |
Why?
|
| Pediatrics | 3 | 2018 | 1155 | 0.390 |
Why?
|
| Tuberculosis Vaccines | 1 | 2011 | 13 | 0.390 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 578 | 0.360 |
Why?
|
| Cystic Fibrosis | 4 | 2021 | 257 | 0.360 |
Why?
|
| United States | 25 | 2016 | 10885 | 0.360 |
Why?
|
| Drug Therapy, Combination | 9 | 2019 | 1163 | 0.340 |
Why?
|
| Mycobacterium avium Complex | 2 | 2019 | 17 | 0.340 |
Why?
|
| Central Nervous System Bacterial Infections | 1 | 2010 | 5 | 0.340 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2024 | 449 | 0.330 |
Why?
|
| Vaccination | 3 | 2011 | 952 | 0.320 |
Why?
|
| Disease Management | 2 | 2016 | 521 | 0.320 |
Why?
|
| Physicians | 1 | 2015 | 582 | 0.310 |
Why?
|
| Adoption | 1 | 2008 | 16 | 0.310 |
Why?
|
| Cross Reactions | 2 | 2021 | 193 | 0.300 |
Why?
|
| Brain | 1 | 2019 | 3008 | 0.290 |
Why?
|
| Nontuberculous Mycobacteria | 4 | 2021 | 25 | 0.280 |
Why?
|
| Diagnosis, Differential | 9 | 2014 | 1893 | 0.280 |
Why?
|
| Quality Improvement | 1 | 2013 | 638 | 0.280 |
Why?
|
| Pyrazinamide | 3 | 2002 | 12 | 0.280 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2008 | 108 | 0.270 |
Why?
|
| Paresis | 1 | 2007 | 36 | 0.270 |
Why?
|
| Endemic Diseases | 1 | 2006 | 57 | 0.250 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2013 | 133 | 0.250 |
Why?
|
| Tuberculosis, Spinal | 2 | 2013 | 8 | 0.250 |
Why?
|
| Emigration and Immigration | 2 | 2004 | 81 | 0.240 |
Why?
|
| Combined Modality Therapy | 4 | 2018 | 1247 | 0.230 |
Why?
|
| Child Health Services | 2 | 2003 | 87 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 6 | 2024 | 1265 | 0.230 |
Why?
|
| Patient Compliance | 4 | 2002 | 475 | 0.230 |
Why?
|
| Students | 2 | 2016 | 251 | 0.230 |
Why?
|
| Respiration, Artificial | 2 | 2018 | 462 | 0.220 |
Why?
|
| Severity of Illness Index | 5 | 2016 | 2903 | 0.220 |
Why?
|
| Skin Tests | 3 | 2016 | 78 | 0.220 |
Why?
|
| Acquired Immunodeficiency Syndrome | 4 | 1992 | 235 | 0.220 |
Why?
|
| AIDS-Related Opportunistic Infections | 6 | 2010 | 136 | 0.210 |
Why?
|
| Neoplasms | 3 | 2014 | 2788 | 0.210 |
Why?
|
| Policy | 1 | 2023 | 34 | 0.210 |
Why?
|
| Time Factors | 3 | 2019 | 6309 | 0.210 |
Why?
|
| Clostridium Infections | 2 | 2017 | 245 | 0.200 |
Why?
|
| Models, Theoretical | 1 | 2025 | 359 | 0.200 |
Why?
|
| Pneumonia, Bacterial | 2 | 2015 | 76 | 0.200 |
Why?
|
| False Positive Reactions | 2 | 2021 | 144 | 0.200 |
Why?
|
| Skin Diseases, Bacterial | 2 | 2014 | 23 | 0.200 |
Why?
|
| Thorax | 2 | 2019 | 72 | 0.190 |
Why?
|
| Developing Countries | 4 | 2010 | 269 | 0.190 |
Why?
|
| Mycobacterium bovis | 1 | 2021 | 30 | 0.190 |
Why?
|
| Radiography, Thoracic | 3 | 2011 | 154 | 0.180 |
Why?
|
| Mycobacterium avium | 1 | 2000 | 15 | 0.180 |
Why?
|
| Uterine Cervical Diseases | 1 | 2000 | 6 | 0.180 |
Why?
|
| Clinical Trials as Topic | 3 | 2015 | 1090 | 0.170 |
Why?
|
| Follow-Up Studies | 6 | 2014 | 5153 | 0.170 |
Why?
|
| Disease Outbreaks | 2 | 1992 | 323 | 0.170 |
Why?
|
| Reference Standards | 3 | 2015 | 238 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 848 | 0.170 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2020 | 3587 | 0.160 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 296 | 0.160 |
Why?
|
| Pseudomonas Infections | 2 | 2013 | 115 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2019 | 2090 | 0.160 |
Why?
|
| Personnel, Hospital | 2 | 2013 | 34 | 0.160 |
Why?
|
| Spotted Fever Group Rickettsiosis | 1 | 2018 | 5 | 0.150 |
Why?
|
| Surveys and Questionnaires | 5 | 2016 | 3726 | 0.150 |
Why?
|
| Rickettsia | 1 | 2018 | 13 | 0.150 |
Why?
|
| Health Personnel | 2 | 2015 | 505 | 0.150 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2016 | 141 | 0.150 |
Why?
|
| Debridement | 1 | 2018 | 89 | 0.150 |
Why?
|
| T-Lymphocytes | 1 | 2006 | 1708 | 0.150 |
Why?
|
| Ventilators, Mechanical | 1 | 2018 | 35 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2019 | 269 | 0.140 |
Why?
|
| Health Education | 2 | 2016 | 222 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2016 | 117 | 0.140 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2016 | 790 | 0.140 |
Why?
|
| Recurrence | 4 | 2017 | 1425 | 0.140 |
Why?
|
| Risk Assessment | 4 | 2015 | 3435 | 0.140 |
Why?
|
| Adult | 21 | 2018 | 29471 | 0.130 |
Why?
|
| Angiostrongylus cantonensis | 1 | 2016 | 9 | 0.130 |
Why?
|
| Young Adult | 7 | 2023 | 8987 | 0.130 |
Why?
|
| Strongylida Infections | 1 | 2016 | 15 | 0.130 |
Why?
|
| Consensus | 4 | 2024 | 634 | 0.130 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2018 | 480 | 0.130 |
Why?
|
| Community-Acquired Infections | 2 | 2015 | 240 | 0.130 |
Why?
|
| Fever of Unknown Origin | 1 | 2016 | 45 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2018 | 384 | 0.130 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 1 | 2015 | 8 | 0.130 |
Why?
|
| Aftercare | 1 | 2017 | 148 | 0.130 |
Why?
|
| Prognosis | 7 | 2016 | 4607 | 0.130 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2014 | 314 | 0.130 |
Why?
|
| Prevalence | 3 | 2018 | 2451 | 0.120 |
Why?
|
| Inflammation | 2 | 2017 | 1428 | 0.120 |
Why?
|
| Tuberculosis, Osteoarticular | 1 | 1995 | 4 | 0.120 |
Why?
|
| Drug Combinations | 1 | 2016 | 266 | 0.120 |
Why?
|
| Soft Tissue Infections | 2 | 2014 | 85 | 0.120 |
Why?
|
| Bacterial Vaccines | 2 | 1995 | 100 | 0.120 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2015 | 53 | 0.120 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2015 | 41 | 0.120 |
Why?
|
| Cat-Scratch Disease | 1 | 2015 | 33 | 0.120 |
Why?
|
| Adolescent Behavior | 1 | 2016 | 168 | 0.120 |
Why?
|
| Predictive Value of Tests | 3 | 2015 | 2142 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 150 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 2 | 2014 | 511 | 0.120 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2015 | 58 | 0.120 |
Why?
|
| Botswana | 1 | 2014 | 76 | 0.120 |
Why?
|
| Drug Resistance, Multiple | 2 | 2010 | 49 | 0.110 |
Why?
|
| Communicable Diseases | 1 | 2016 | 160 | 0.110 |
Why?
|
| Drug Costs | 1 | 2014 | 60 | 0.110 |
Why?
|
| Hospital Mortality | 2 | 2018 | 1027 | 0.110 |
Why?
|
| Sex Distribution | 3 | 2015 | 301 | 0.110 |
Why?
|
| Age Distribution | 3 | 2015 | 415 | 0.110 |
Why?
|
| Referral and Consultation | 2 | 2013 | 539 | 0.110 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2014 | 93 | 0.110 |
Why?
|
| Diarrhea | 1 | 2015 | 316 | 0.110 |
Why?
|
| Allografts | 1 | 2014 | 192 | 0.110 |
Why?
|
| Drug Resistance, Microbial | 4 | 1999 | 193 | 0.100 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 607 | 0.100 |
Why?
|
| Respiratory Insufficiency | 1 | 2015 | 232 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 585 | 0.100 |
Why?
|
| Poverty | 1 | 2016 | 418 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 1994 | 174 | 0.100 |
Why?
|
| Cross-Cultural Comparison | 1 | 2012 | 59 | 0.100 |
Why?
|
| Family Health | 2 | 2011 | 259 | 0.100 |
Why?
|
| Osteomyelitis | 1 | 1995 | 205 | 0.100 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 364 | 0.100 |
Why?
|
| Clofazimine | 2 | 2022 | 7 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 5 | 2010 | 1587 | 0.100 |
Why?
|
| Neck | 2 | 2008 | 137 | 0.100 |
Why?
|
| Drug Design | 1 | 2013 | 146 | 0.100 |
Why?
|
| Nephrotic Syndrome | 1 | 2012 | 46 | 0.100 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2011 | 7 | 0.100 |
Why?
|
| Markov Chains | 1 | 2012 | 84 | 0.100 |
Why?
|
| World Health Organization | 1 | 2011 | 100 | 0.090 |
Why?
|
| Immunization Schedule | 1 | 1991 | 101 | 0.090 |
Why?
|
| Research Design | 2 | 2013 | 690 | 0.090 |
Why?
|
| Evidence-Based Medicine | 2 | 2013 | 632 | 0.090 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 166 | 0.090 |
Why?
|
| Steroids | 1 | 2012 | 203 | 0.090 |
Why?
|
| Polymorphism, Genetic | 2 | 2005 | 812 | 0.090 |
Why?
|
| Cytokines | 1 | 2017 | 1290 | 0.090 |
Why?
|
| Pregnancy | 5 | 2024 | 7172 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2014 | 1252 | 0.090 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 97 | 0.090 |
Why?
|
| Mandatory Programs | 1 | 2010 | 5 | 0.090 |
Why?
|
| HIV | 1 | 2011 | 180 | 0.090 |
Why?
|
| Hospitals | 1 | 2013 | 398 | 0.090 |
Why?
|
| Neurosurgical Procedures | 1 | 2013 | 308 | 0.090 |
Why?
|
| Guideline Adherence | 1 | 2013 | 382 | 0.090 |
Why?
|
| Coinfection | 1 | 2011 | 172 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2013 | 1495 | 0.080 |
Why?
|
| Public Health | 3 | 2016 | 260 | 0.080 |
Why?
|
| Carrier State | 1 | 2010 | 77 | 0.080 |
Why?
|
| Meningitis, Bacterial | 1 | 2010 | 94 | 0.080 |
Why?
|
| Immunization | 1 | 2010 | 307 | 0.080 |
Why?
|
| Prospective Studies | 7 | 2021 | 6137 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 1991 | 271 | 0.080 |
Why?
|
| Viral Vaccines | 1 | 1991 | 334 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2015 | 4783 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1017 | 0.080 |
Why?
|
| Animals | 5 | 2018 | 34184 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2008 | 116 | 0.070 |
Why?
|
| Radiography | 3 | 2015 | 828 | 0.070 |
Why?
|
| Urban Population | 1 | 1989 | 226 | 0.070 |
Why?
|
| Biomarkers | 1 | 2017 | 3063 | 0.070 |
Why?
|
| Internationality | 1 | 2008 | 131 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2008 | 356 | 0.070 |
Why?
|
| Influenza, Human | 2 | 2010 | 658 | 0.070 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2010 | 222 | 0.070 |
Why?
|
| Nutrition Assessment | 1 | 2008 | 136 | 0.070 |
Why?
|
| Bacteriological Techniques | 3 | 2012 | 86 | 0.070 |
Why?
|
| Tuberculoma, Intracranial | 1 | 2007 | 7 | 0.070 |
Why?
|
| Breast Feeding | 1 | 2008 | 220 | 0.070 |
Why?
|
| Brain Diseases | 2 | 1995 | 300 | 0.070 |
Why?
|
| Amphotericin B | 1 | 1987 | 90 | 0.070 |
Why?
|
| Hospitalization | 2 | 1993 | 1783 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2008 | 380 | 0.070 |
Why?
|
| Bacteremia | 1 | 2010 | 407 | 0.060 |
Why?
|
| Treatment Failure | 3 | 2016 | 342 | 0.060 |
Why?
|
| Disease Progression | 2 | 2010 | 2052 | 0.060 |
Why?
|
| South Africa | 1 | 2006 | 100 | 0.060 |
Why?
|
| Candidiasis | 1 | 1987 | 129 | 0.060 |
Why?
|
| Dysentery, Bacillary | 1 | 1985 | 10 | 0.060 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 269 | 0.060 |
Why?
|
| Caregivers | 1 | 2011 | 578 | 0.060 |
Why?
|
| Molecular Epidemiology | 3 | 2013 | 155 | 0.060 |
Why?
|
| Colonic Diseases | 1 | 1985 | 38 | 0.060 |
Why?
|
| Ethambutol | 1 | 2004 | 7 | 0.060 |
Why?
|
| Intestinal Perforation | 1 | 1985 | 60 | 0.060 |
Why?
|
| Global Burden of Disease | 1 | 2025 | 25 | 0.060 |
Why?
|
| Cation Transport Proteins | 1 | 2005 | 97 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2010 | 558 | 0.060 |
Why?
|
| Thoracic Diseases | 1 | 2004 | 6 | 0.060 |
Why?
|
| Infant, Premature, Diseases | 1 | 1987 | 241 | 0.060 |
Why?
|
| Longitudinal Studies | 1 | 2008 | 1327 | 0.060 |
Why?
|
| Syndrome | 1 | 2007 | 1118 | 0.060 |
Why?
|
| Pneumonia | 1 | 1987 | 326 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 1691 | 0.060 |
Why?
|
| Tuberculosis, Cutaneous | 1 | 2003 | 4 | 0.060 |
Why?
|
| Prednisone | 2 | 2016 | 275 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2005 | 3142 | 0.050 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 1091 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2025 | 283 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2003 | 114 | 0.050 |
Why?
|
| Linezolid | 1 | 2022 | 25 | 0.050 |
Why?
|
| 3' Untranslated Regions | 1 | 2003 | 165 | 0.050 |
Why?
|
| Nutrition Disorders | 1 | 2002 | 32 | 0.050 |
Why?
|
| Algorithms | 3 | 2010 | 1616 | 0.050 |
Why?
|
| Visitors to Patients | 1 | 2002 | 9 | 0.050 |
Why?
|
| Standard of Care | 1 | 2023 | 130 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2018 | 3287 | 0.050 |
Why?
|
| Ethionamide | 1 | 2002 | 1 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2023 | 236 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2023 | 210 | 0.050 |
Why?
|
| Genotype | 3 | 2016 | 2557 | 0.050 |
Why?
|
| Body Fluids | 2 | 1996 | 47 | 0.050 |
Why?
|
| Lung | 1 | 2009 | 1491 | 0.050 |
Why?
|
| Lymph Node Excision | 2 | 2000 | 161 | 0.050 |
Why?
|
| Travel | 2 | 2015 | 116 | 0.050 |
Why?
|
| DNA, Bacterial | 2 | 1995 | 474 | 0.050 |
Why?
|
| Uganda | 1 | 2021 | 68 | 0.050 |
Why?
|
| Drug and Narcotic Control | 1 | 2020 | 18 | 0.050 |
Why?
|
| Survival Rate | 2 | 2015 | 2035 | 0.050 |
Why?
|
| Measles | 2 | 1991 | 32 | 0.040 |
Why?
|
| Sputum | 1 | 2021 | 105 | 0.040 |
Why?
|
| Mass Chest X-Ray | 1 | 2020 | 1 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1993 | 824 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 66 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 107 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2020 | 80 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2001 | 174 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2018 | 59 | 0.040 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2018 | 63 | 0.040 |
Why?
|
| Philippines | 1 | 1997 | 23 | 0.030 |
Why?
|
| Immunocompetence | 1 | 1997 | 33 | 0.030 |
Why?
|
| Proteus mirabilis | 1 | 2016 | 12 | 0.030 |
Why?
|
| Peru | 1 | 2016 | 47 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2016 | 32 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2016 | 91 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 1997 | 113 | 0.030 |
Why?
|
| North America | 1 | 2016 | 240 | 0.030 |
Why?
|
| Meningitis | 1 | 2016 | 98 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 565 | 0.030 |
Why?
|
| X-Rays | 1 | 1995 | 27 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2005 | 143 | 0.030 |
Why?
|
| Quality Control | 1 | 2015 | 119 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2020 | 930 | 0.030 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2015 | 16 | 0.030 |
Why?
|
| Serologic Tests | 1 | 1995 | 118 | 0.030 |
Why?
|
| India | 1 | 2015 | 219 | 0.030 |
Why?
|
| Eosinophilia | 1 | 2016 | 101 | 0.030 |
Why?
|
| DNA Transposable Elements | 1 | 1996 | 177 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 1995 | 153 | 0.030 |
Why?
|
| Mastoiditis | 1 | 1995 | 33 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 428 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2016 | 447 | 0.030 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 1995 | 65 | 0.030 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2014 | 52 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 112 | 0.030 |
Why?
|
| Tympanic Membrane | 1 | 1994 | 18 | 0.030 |
Why?
|
| Hydrocephalus | 2 | 2013 | 244 | 0.030 |
Why?
|
| Leg | 1 | 1995 | 160 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2015 | 162 | 0.030 |
Why?
|
| Infliximab | 1 | 2014 | 67 | 0.030 |
Why?
|
| Automobile Driving | 1 | 1994 | 28 | 0.030 |
Why?
|
| Middle Ear Ventilation | 1 | 1994 | 29 | 0.030 |
Why?
|
| Pregnancy in Adolescence | 1 | 1994 | 50 | 0.030 |
Why?
|
| Head | 1 | 1994 | 103 | 0.030 |
Why?
|
| Gastrostomy | 1 | 2014 | 85 | 0.030 |
Why?
|
| Internet | 1 | 2016 | 383 | 0.030 |
Why?
|
| Risk-Taking | 1 | 1994 | 94 | 0.030 |
Why?
|
| Pregnancy Outcome | 1 | 1997 | 589 | 0.030 |
Why?
|
| Linkage Disequilibrium | 2 | 2005 | 309 | 0.030 |
Why?
|
| Otitis Media | 1 | 1994 | 84 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 181 | 0.030 |
Why?
|
| Feces | 1 | 2017 | 718 | 0.030 |
Why?
|
| Violence | 1 | 1994 | 116 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 1997 | 873 | 0.030 |
Why?
|
| Paraplegia | 1 | 2013 | 94 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2013 | 34 | 0.030 |
Why?
|
| Intestines | 1 | 2017 | 572 | 0.030 |
Why?
|
| Abscess | 1 | 1994 | 139 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2004 | 320 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 1993 | 212 | 0.030 |
Why?
|
| Hyponatremia | 1 | 2013 | 73 | 0.020 |
Why?
|
| Societies, Medical | 1 | 1996 | 689 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 757 | 0.020 |
Why?
|
| Organ Transplantation | 1 | 2014 | 165 | 0.020 |
Why?
|
| Length of Stay | 1 | 2018 | 1309 | 0.020 |
Why?
|
| Skin Diseases, Infectious | 1 | 1992 | 24 | 0.020 |
Why?
|
| Diphtheria | 1 | 1991 | 15 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2012 | 112 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1993 | 225 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 400 | 0.020 |
Why?
|
| Biopsy | 1 | 1995 | 1239 | 0.020 |
Why?
|
| Haemophilus Infections | 1 | 1991 | 91 | 0.020 |
Why?
|
| Haemophilus influenzae | 1 | 1991 | 130 | 0.020 |
Why?
|
| Antigens, Bacterial | 1 | 1993 | 314 | 0.020 |
Why?
|
| Whooping Cough | 1 | 1991 | 58 | 0.020 |
Why?
|
| DNA Probes | 1 | 1991 | 124 | 0.020 |
Why?
|
| Critical Illness | 1 | 2015 | 600 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2010 | 35 | 0.020 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2010 | 8 | 0.020 |
Why?
|
| Brain Ischemia | 1 | 2013 | 261 | 0.020 |
Why?
|
| Health Promotion | 1 | 1994 | 392 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1810 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2015 | 1180 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 2014 | 339 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 1993 | 776 | 0.020 |
Why?
|
| Leukocidins | 1 | 2010 | 37 | 0.020 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2010 | 92 | 0.020 |
Why?
|
| Exotoxins | 1 | 2010 | 44 | 0.020 |
Why?
|
| HIV-1 | 1 | 1993 | 467 | 0.020 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2010 | 38 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 1994 | 459 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2014 | 494 | 0.020 |
Why?
|
| Pneumococcal Infections | 1 | 1991 | 274 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 1531 | 0.020 |
Why?
|
| Cambodia | 1 | 1988 | 11 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2010 | 175 | 0.020 |
Why?
|
| Encephalitis | 1 | 1990 | 110 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 1994 | 606 | 0.020 |
Why?
|
| Chronic Disease | 2 | 1994 | 1192 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1992 | 384 | 0.020 |
Why?
|
| Craniotomy | 1 | 1988 | 108 | 0.020 |
Why?
|
| Research | 1 | 1989 | 263 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 1989 | 222 | 0.020 |
Why?
|
| Infectious Mononucleosis | 1 | 1987 | 15 | 0.020 |
Why?
|
| Species Specificity | 1 | 1987 | 550 | 0.020 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1987 | 28 | 0.020 |
Why?
|
| Hyperbilirubinemia | 1 | 1987 | 41 | 0.020 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1987 | 44 | 0.020 |
Why?
|
| Enterobacteriaceae Infections | 1 | 1987 | 55 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1987 | 388 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 1989 | 387 | 0.020 |
Why?
|
| Keratitis | 1 | 1987 | 116 | 0.020 |
Why?
|
| Shigella flexneri | 1 | 1985 | 13 | 0.020 |
Why?
|
| Bacterial Typing Techniques | 1 | 2005 | 102 | 0.020 |
Why?
|
| Absorption | 1 | 2004 | 52 | 0.010 |
Why?
|
| Kinetics | 1 | 1987 | 1325 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2005 | 187 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2010 | 887 | 0.010 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2004 | 21 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 660 | 0.010 |
Why?
|
| Pericardial Effusion | 1 | 2004 | 65 | 0.010 |
Why?
|
| Middle Aged | 4 | 2010 | 26716 | 0.010 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2003 | 14 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2004 | 101 | 0.010 |
Why?
|
| Aged | 3 | 2004 | 19691 | 0.010 |
Why?
|
| Patient Isolation | 1 | 2002 | 14 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 2002 | 30 | 0.010 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2002 | 41 | 0.010 |
Why?
|
| Family | 1 | 2005 | 565 | 0.010 |
Why?
|
| Half-Life | 1 | 2002 | 157 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2002 | 683 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1987 | 4357 | 0.010 |
Why?
|
| Models, Biological | 1 | 2002 | 1461 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2002 | 2880 | 0.010 |
Why?
|
| Cranial Nerves | 1 | 1995 | 19 | 0.010 |
Why?
|
| Aging | 1 | 2002 | 1189 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2003 | 2625 | 0.010 |
Why?
|
| Granulation Tissue | 1 | 1994 | 12 | 0.010 |
Why?
|
| Mastoid | 1 | 1994 | 24 | 0.010 |
Why?
|
| Aminoglycosides | 1 | 1994 | 44 | 0.010 |
Why?
|
| Drainage | 1 | 1994 | 258 | 0.010 |
Why?
|
| Base Sequence | 1 | 1996 | 3099 | 0.010 |
Why?
|
| Wound Healing | 1 | 1995 | 458 | 0.010 |
Why?
|
| Mice | 1 | 1987 | 17746 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 3881 | 0.010 |
Why?
|
| Shigella sonnei | 1 | 1987 | 3 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1995 | 3068 | 0.000 |
Why?
|
| Cornea | 1 | 1987 | 653 | 0.000 |
Why?
|